What drug wholesalers do

Three wholesalers account for more than 90 percent of US wholesale drug distribution, according to a February 2026 memo from House Energy and Commerce Committee majority staff¹. The same memo cited an industry estimate that distributors handle 95 percent of all prescription medicine sales in the country.

Wholesalers are the least visible link in the chain that carries a pill from the factory to the pharmacy. Patients never deal with them, and their contracts are confidential. For generic drugs they do much more than move boxes. They hold the inventory that cushions supply problems, process the payments that make hospital contract prices work, bargain with generic makers that sell interchangeable products, and, under a 2013 law, keep the electronic records that trace each package.

Moving and holding the product

A wholesaler buys drugs from manufacturers, stores them in distribution centers and delivers them to pharmacies, hospitals, clinics and physician offices. The House committee memo lists the core services as receiving and repackaging products for distribution, inventory management and financial risk management. Wholesalers typically buy at the manufacturer's list price, the wholesale acquisition cost (WAC), less a percentage discount, the memo says¹. GxRadar's guide to WAC, AWP, NADAC and other benchmarks explains how that list price relates to what pharmacies pay.

Inventory is thinner than many people assume. In a 2011 analysis of drug shortages², the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE) reported that one major sterile injectable manufacturer estimated it usually held three to four months of inventory, and that wholesalers carried another 30 days' worth. Other makers, ASPE noted, had notified FDA of shortages when they had a month or less of supply left. FDA's 2019 shortage task force report³ said manufacturers, purchasing groups and distributors had moved toward "just in time" inventory management, "so there is little redundancy in the supply chain when a disruption occurs." Current shortages are on GxRadar's shortage tracker, and the causes are laid out in Why drug shortages happen.

Buying power over generic prices

Because FDA rates many generic versions of a drug as therapeutically equivalent, a large buyer can shop among manufacturers molecule by molecule and move its volume to whichever one offers the lower price. HHS's 2024 white paper on drug shortages⁴ said the concentrated wholesaler industry influences the purchase and distribution of prescription drugs "in setting generic drug prices," and grouped wholesalers with purchasing organizations and benefit managers as intermediaries "which some argue have applied strong downward price pressures to generic drugs." It singled out low-price clauses that let a buyer walk away from a contract if another manufacturer offers less.

GxRadar's own NADAC data trace the result. The GxRadar generic price index for a basket of 43 common generics stood at 47.4 in October 2026 against 100 in January 2014, a drop of about 53 percent. The long deflation of generic prices covers that slide, and Why generic prices fall as competitors enter covers the competition side. What low prices do to manufacturers is the subject of The economics of making a generic.

Chargebacks and hospital contract prices

Wholesalers also sit in the middle of hospital pricing. Hospitals usually buy generic injectables at prices negotiated by a group purchasing organization (GPO), but the GPO never takes possession of the drugs. ASPE described the mechanics² in 2011. A wholesaler takes possession of the drug at the wholesale acquisition price and sells it to the GPO's members at the negotiated price. The manufacturer then issues the wholesaler a "chargeback" for the difference if its list price is higher than the GPO price.

The same brief put five GPOs at 85 to 90 percent of their market at the time. How the underlying hospital contracts are negotiated, and what federal reports say about their effect on injectable supply, is in Group purchasing organizations and hospitals and How hospitals buy drugs.

The tracing job under DSCSA

Under the Drug Supply Chain Security Act (DSCSA), enacted in 2013, manufacturers, wholesale distributors, dispensers and repackagers must provide, receive and maintain documentation about prescription drugs and their chain of ownership from manufacturer to dispenser, according to FDA⁵. The law's enhanced requirements make that documentation electronic and traceable at the package level, and FDA has phased them in by type of trading partner.

Wholesalers got a little more time than manufacturers. In a 2024 exemption notice⁶, FDA exempted eligible wholesale distributors from certain enhanced requirements from Nov. 27, 2024, until Aug. 27, 2025. Small pharmacies, often a wholesaler's smallest customers, have the longest runway; FDA's current exemption⁷ for them runs to Nov. 27, 2027. Package-level records matter most when a product has to be pulled, and GxRadar's recall records show hundreds of FDA-classified drug recalls every year, including 212 records from July 30 to Oct. 28, 2026.

What to watch

The House committee memo, prepared for a Feb. 11, 2026, hearing on the drug supply chain, noted growing vertical integration by the largest wholesalers, which now operate businesses¹ that include specialty and retail pharmacies, purchasing organizations and provider groups. HHS's white paper, for its part, floated a Hospital Resilient Supply Program that would tie financial incentives or penalties for hospitals to their purchasing practices, a change that would run through the same wholesaler and purchasing contracts. The next fixed date is the Nov. 27, 2027, end of FDA's small-pharmacy DSCSA exemption.